About 4M THERAPEUTICS INC.
4M Therapeutics develops targeted therapies for neuropsychiatric and neurodegenerative conditions using a living human brain cell platform derived from induced pluripotent stem cells. Their lead candidate, 4MT2001, is a GSK3β inhibitor for bipolar disorder.
Development of targeted therapies for central nervous system disordersUse of living human brain cell platform derived from induced pluripotent stem cellsResearch on neuroplasticity, neurogenesis, and neuroinflammation pathwaysIdentification and optimization of candidate medicines
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to 4M THERAPEUTICS INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.